Wu et al. (61) evaluated the combination of pembrolizumab with chemotherapy and chemotherapy in patients with EGFR or ALK mutation-negative sq-NSCLC, and showed that the combination regimen was not cost-effective regardless of the PD-L1 expression level. The gene discussed is ALK; the disease is non-small cell lung carcinoma.